Amylyx’s Relyvrio Could See Fast Sales Growth, But Also Spark Pricing Debate
Interpret Survival Analysis “Cautiously,” Label Advises
The FDA gave full approval based on a Phase II study, without the need for Phase III confirmatory data, for Amylyx’s ALS drug Relyvrio but the $158,000 WAC could spark a debate over pricing.
